Journey Medical Corp Overview
Industry: Drug Manufacturers Specialty & Generic
Sector: Healthcare
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Zilxi, a topical minocycline treatment for inflammatory lesions; Ximino, an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm cream and solution for topical use. It also sells doxycycline hyclate tablets, minocycline hydrocholoride capsules, and sulconazole nitrate cream and solution. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc. Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosi Read MoreMavefund brings filings, fundamentals, valuation, price history and news for Journey Medical Corp into one research view. The sections below show what strengthens or weakens the research case.
Score
Reported Results
What the company reported, with filing details kept small.
Quarterly result summary
Revenue was $18.5M (reported). Net loss was -$0.3M (-92% YoY). G&A expense was $10.9M.
What changed
- Revenue reported to $18.5M.
- Net loss -92% YoY to -$0.3M.
- Adjusted EBITDA -701% YoY to $2.9M.
Guidance / outlook
No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.
Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.
Other recent earnings materials
Prediction-grade evidence
Recent News
Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.
Journey Medical Corp (DERM) (Q2 2026) Earnings Call Highlights: Emrosi Surges 20% Sequentially, ...
Headline from Yahoo Finance: Journey Medical Corp (DERM) (Q2 2026) Earnings Call Highlights: Emrosi Surges 20% Sequentially, .
Journey Medical Corporation Q2 2026 Earnings Call Summary
Headline from Yahoo Finance: Journey Medical Corporation Q2 2026 Earnings Call Summary.
Here's What Key Metrics Tell Us About Journey Medical (DERM) Q2 Earnings
Headline from Yahoo Finance: Here's What Key Metrics Tell Us About Journey Medical (DERM) Q2 Earnings.
Earnings call transcript: Journey Medical tops Q2 2026 forecasts as stock rises
Headline from Investing.com: Earnings call transcript: Journey Medical tops Q2 2026 forecasts as stock rises.
Earnings call transcript: Journey Medical posts Q2 2026 revenue gain, turns EBITDA positive
Headline from Investing.com: Earnings call transcript: Journey Medical posts Q2 2026 revenue gain, turns EBITDA positive.
Journey Medical earnings beat by $0.12, revenue topped estimates
Headline from Investing.com: Journey Medical earnings beat by $0.12, revenue topped estimates.
Earnings Per Share
Return on Equity
ROE
Company —
Sector Median —
ROE
Company —
Sector Median —
ROE
Company —
Sector Median —
ROE
Company —
Sector Median —
Metric chart temporarily unavailable.
Net Margin
Net Margin
Company —
Sector Median —
Net Margin
Company —
Sector Median —
Net Margin
Company —
Sector Median —
Net Margin
Company —
Sector Median —
Metric chart temporarily unavailable.
Leverage
Leverage
Company —
Sector Median —
Leverage
Company —
Sector Median —
Leverage
Company —
Sector Median —
Leverage
Company —
Sector Median —
Metric chart temporarily unavailable.
Financial Statements
Company-reported SEC EDGAR facts organized into the three core statements.
Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.